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ABSTRACT 27 
Extra-intestinal manifestations (EIM) are common in inflammatory bowel disease (IBD). One 28 
such EIM is sub-clinical pulmonary inflammation, which occurs in up to 50% of IBD patients. 29 
In animal models of colitis, pulmonary inflammation is driven by neutrophilic infiltrations, 30 
primarily in response to the systemic bacteraemia and increased bacterial load in the lungs.  31 
Platelet activating factor receptor (PAFR) plays a critical role in regulating pulmonary 32 
responses to infection in conditions, such as chronic obstructive pulmonary disease (COPD) 33 
and asthma. We investigated the role of PAFR in pulmonary EIMs of IBD, using dextran 34 
sulfate sodium (DSS) and anti-CD40 murine models of colitis. Both models induced 35 
neutrophilic inflammation, with increased TNF and IL-1b levels, bacterial load and PAFR 36 
protein expression in mouse lungs. Antagonism of PAFR decreased lung neutrophilia, TNF 37 
and IL-1b in an NLRP3 inflammasome-dependent manner. Lipopolysaccharide (LPS) from 38 
phosphorylcholine (ChoP)-positive bacteria induced NLRP3 and caspase-1 proteins in human 39 
alveolar epithelial cells, however antagonism of PAFR prevented NLRP3 activation by ChoP. 40 
Amoxicillin reduced bacterial populations in the lungs and reduced NLRP3 inflammasome 41 
protein levels, but did not reduce PAFR. These data suggest a role for PAFR in microbial 42 
pattern recognition and NLRP3 inflammasome signalling in the lung.  43 
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INTRODUCTION 47 
Inflammatory bowel disease (IBD) including Crohn’s diseases (CD) and ulcerative colitis (UC) 48 
are chronic diseases of gastrointestinal (GI) tract.1 Although the pathology between CD and 49 
UC differs, they share a number of common characteristics and co-morbidities, the chief of 50 
which is arguably the loss of epithelial barrier function.2 This loss of epithelial integrity 51 
promotes bacteraemia in IBD patients3-5 and these pathologies are apparent in animal models 52 
of colitis.6, 7 In IBD patients, bacteraemia can promote extra-intestinal inflammation and 53 
approximately half of IBD patients have secondary organ pathologies that contribute 54 
significantly to disease morbidity.8 An increasing number of studies suggest that abnormal lung 55 
pathology is a common feature of IBD,9, 10 with subclinical disease observed in over one third 56 
of IBD patients.11 While some therapies can promote lung damage,12 in the majority of cases 57 
pulmonary disease associated with IBD is idiopathic, and animal studies have demonstrated 58 
that lung pathologies similar to those observed in IBD patients are evident in animal models of 59 
colitis.7, 13, 14 Our recent studies suggest that pulmonary manifestations of colitis arise from 60 
neutrophilia associated with loss of intestinal epithelial integrity and subsequent bacteraemia.7 61 
An increased bacterial load in the lungs may be the initiating factor for the observed pulmonary 62 
neutrophilia, although the pathway initiating this response is unclear. 63 
  64 
In respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and 65 
asthma, the majority of acute exacerbations are driven by bacterial and viral infection,15 with 66 
pathogens often exploiting cellular receptors and adhesion molecules upregulated during 67 
inflammatory processes.16 One such receptor, platelet-activating factor (PAFR) is a G protein 68 
coupled receptor expressed on epithelial and endothelial cells, macrophages and neutrophils.17 69 
PAFR is a hypoxia-responsive gene18 and PAFR protein levels are increased in inflamed lungs 70 
from patients with asthma19 and COPD.20 PAFR has affinity for bacterial phosphorylcholine 71 
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(ChoP) moieties21 and increased expression of PAFR is associated with both Gram-negative 72 
and Gram-positive infection.22 Thus, in conditions of increased pulmonary stress of infection, 73 
PAFR may represent a crucial mediator of inflammation and inhibition or antagonism of PAFR 74 
has been considered as a therapeutic strategy for the management of pulmonary disease.23, 24 75 
 76 
In the pulmonary inflammation associated with colitis, bacteraemia is an initiating 77 
factor and pulmonary inflammation is dependent on neutrophil recruitment from the bone 78 
marrow.7 While these animals exhibit increased bacterial load in the lungs, the mechanism 79 
initiating neutrophil recruitment to the lung is unclear. Here we hypothesized that increased 80 
bacterial burden in the lung, driven by colitis-associated bacteremia, activates anti-microbial 81 
responses that drive neutrophil recruitment. Using dextran sulfate sodium (DSS) and anti-82 
CD40 models of colitis, we identified increases in PAFR in pulmonary epithelial cells and 83 
neutrophils associated with increased bacterial load and NLRP3 inflammasome activation in 84 
the lungs. Antagonism of PAFR reduced neutrophil but not macrophage recruitment to the lung 85 
and reduced neutrophil extracellular traps (NETs) formation in the parenchyma. In vitro studies 86 
with pulmonary epithelial cells demonstrated NLRP3 activation, cleavage of caspase-1 and IL-87 
1β secretion in response ChoP-positive, but not ChoP negative LPS. However, this 88 
inflammasome activation was inhibited by PAFR antagonism. Further, PAFR induction and 89 
inflammasome activation in the lungs of DSS colitis animals was inhibited by antibiotic 90 
treatment. These data implicate PAFR-microbe interactions as a key modulator of pulmonary 91 
inflammation in colitis and bacteremia, and suggest that PAFR is a microbial sensor regulating 92 
local inflammasome responses. 93 
 94 
RESULTS 95 
Experimental models of colitis induce lung inflammation  96 
 6 
To explore colitis associated with lung inflammation, we employed an acute model of DSS-97 
induced colitis as described previously.7, 13 Colitis features were determined by measuring body 98 
weight and by endoscopy. DSS challenge resulted in significant weight loss by day 4 and 99 
further decrease over days 5 to 7 (Figure 1a). Endoscopic assessment showed increasing 100 
mucosal inflammation and ulceration over time (Figure 1b). DSS challenge increased total 101 
leukocytes, predominately macrophages and neutrophils, in bronchoalveolar lavage fluid 102 
(BALF) from mouse lungs (Figure 1c). Histological analysis demonstrated that inflammatory 103 
cells were predominantly localized around the parenchyma and blood vessels in mouse lungs 104 
after 7 days of DSS challenge (Figure 1d, e).   105 
 106 
We next examined whether innate or adaptive responses were key to neutrophil 107 
recruitment to the lungs. To this end, we employed the anti-CD40 model to induce colitis in 108 
recombinase activating gene 1 (RAG1) deficiency (–/–) mice as they lack mature T and B 109 
cells.25 Significant weight loss was observed in the anti-CD40-treated animals, peaking 3 days 110 
after disease induction (Figure 1f). Endoscopic disease was observed within 2 days of 111 
induction and progressed over the course of the model (Figure 1g). The anti-CD40 challenge 112 
also increased macrophages and neutrophil numbers in BALF and induced lung inflammation 113 
(Figure 1h–j) which were not observed in control mice that received isotype IgG control 114 
antibody. 115 
 116 
Colitis increases PAFR proteins and activates NLRP3 involved inflammasome in mouse 117 
lungs  118 
Our previous studies suggested microbial involvement in colitis-induced lung inflammation.7 119 
In this study, we confirmed that DSS-induced colitis resulted in an increase of bacterial 16S 120 
expression in mouse lungs compared to controls (Figure 2a). Given the importance of PAFR 121 
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in pulmonary infection during inflammatory disease, we measured PAFR proteins in mouse 122 
lungs in our model of DSS-induced lung inflammation and found significantly increased PAFR 123 
protein levels on day 7 post DSS (Figure 2b). These data were mirrored in the anti-CD40 124 
model with 16S expression and PAFR protein significantly increased in mouse lungs by 9 days 125 
post challenge (Figure 2c, d), indicating these are common features in colitis-induced lung 126 
inflammation. 127 
 128 
To understand the role of PAFR in colitis-induced lung inflammation, we investigated 129 
cellular sources of PAFR in lungs. Given the consistent increase in pulmonary neutrophils 130 
observed in colitis models7, lung sections were stained with PAFR and Ly6G by 131 
immunofluorescence. Increased PAFR staining was observed in the parenchymal area, and 132 
alveolar epithelial cells (according to morphology) and neutrophils were the predominant cell 133 
types to produce PAFR in mouse lungs (Figure 2e). To confirm the cellular source of PAFR, 134 
we isolated single cell suspensions from mouse lungs and co-stained cell phenotyping markers 135 
and PAFR to identify and enumerate by flow cytometry. PAFR+ epithelial cells (CD45–136 
Epcam+, Figure 2f and Supplementary Figure S1a), macrophages (CD45+F4/80+, Figure 2g 137 
and Supplementary Figure S1b) and neutrophils (CD45+CD11b+Ly6G+, Figure 2h and 138 
Supplementary Figure S1c) were significantly increased in mouse lungs after 7 days DSS 139 
challenge. There were no changes to PAFR+ dendritic cell (CD45+CD11c+) or eosinophil 140 
(CD45+CD11c–SigF+) populations (Supplementary Figure S2) in mouse lungs after 7 days 141 
DSS challenge when compared to controls. 142 
 143 
In line with previous results7, cytokine analysis showed significantly increased levels 144 
of TNF and IL-1b proteins in mouse lungs after DSS challenge (Figure 3a, b). Given that IL-145 
1b is downstream of inflammasome activation, we measured protein levels of molecules 146 
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involved in inflammsome response in mouse lungs. DSS challenge led to significant increases 147 
in NLRP3 and mature caspase-1 proteins in mouse lungs when compared to healthy controls, 148 
however pro-caspase-1 proteins were not changed (Figure 3c, d). To confirm that PAFR 149 
enhances IL-1b secretion by lung epithelial cells via inflammasome activation, we isolated 150 
PAFR+ epithelial cells from mouse lungs after 7 days DSS challenge and controls. The protein 151 
levels of the molecules involved in NLRP3 signalling pathways were measured in cell lysates. 152 
There were significantly increased NLRP3, pro- and mature caspase-1 protein levels in 153 
epithelial cells from mouse lungs after 7 days DSS challenge compared to controls (Figure 3e, 154 
f). Lung epithelial cells from DSS animals also had increased IL-1b compared to healthy 155 
controls (Figure 3g). 156 
 157 
Inhibition of PAFR reduces mouse lung inflammation after DSS challenge 158 
To further investigate the role of PAFR in colitis-induced lung inflammation, we administered 159 
the PAFR antagonist, CV620926 to mice, either intranasally or intravenously from day 4 to 6 160 
of DSS challenge. We chose these time-points based on onset of disease as measured by weight 161 
loss during DSS challenge. On day 7, DSS challenge increased total leukocytes, predominately 162 
macrophage and neutrophils, in the BALF, compared to control animals (Figure 4a–c). 163 
CV6209 treatments with both intranasal and intravenous deliveries significantly reduced 164 
airway neutrophils, but not macrophages (P=0.1302, DSS + CV6209 i.n vs DSS + PBS i.n; 165 
P=0.0528, DSS + CV6209 i.v vs DSS + PBS i.v) in the DSS model. Overall, increases in 166 
inflammatory cells in mouse lungs due to colitis were reduced with CV6209 treatment by both 167 
delivery approaches (Figure 4d, e). Inhibition of PAFR by CV6209 also reduced DSS-induced 168 
TNF (Figure 4f) and IL-1b proteins (Figure 4g) in mouse lungs compared to controls. 169 
Intravenous, but not intranasal delivery of CV6209, to inhibit PAFR reduced DSS-induced IL-170 
6 protein in mouse lungs (Figure 4h). 171 
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 172 
PAFR regulates neutrophil recruitment in mouse lungs after DSS challenge 173 
Given that antagonism of PAFR reduced neutrophils in BALF of DSS animals, we next 174 
examined lung tissue neutrophils and macrophages using flow cytometry. DSS challenge 175 
significantly increased neutrophils and macrophages in mouse lungs by 7 days post challenge 176 
(Figure 5a–c and Supplementary Figure S3). Antagonism of PAFR by CV6209 with both 177 
intranasal and intravenous approaches reduced neutrophils, but not macrophages in mouse 178 
lungs, mirroring our finding of these cells in BALF. 179 
 180 
NETs play a critical role in neutrophil antimicrobial activity,27 and we next assessed 181 
whether antagonism of PAFR influenced NETs in lung tissue. The lung sections were assessed 182 
by immunofluorescence for expression of NET markers, myeloperoxidase (MPO), a 183 
peroxidase enzyme that is released by neutrophils,27 and histone H128 (Figure 5d). DSS 184 
challenge increased the number of MPO and histone H1 positive cells in mouse lungs, however 185 
antagonism of PAFR significantly decreased these cells (Figure 5e). 186 
 187 
PAFR activates the NLRP3 inflammasome signalling pathway  188 
We have shown that antagonism of PAFR reduced IL-1b protein levels in mouse lungs after 189 
DSS challenge. Given that we observed inflammasome activation in the lungs of DSS-induced 190 
colitis animals, we next examined whether PAFR antagonism reduced inflammasome 191 
signalling in mouse lungs after DSS challenge and found that intranasal administration of 192 
CV6209 reduced both NLRP3 and mature caspase-1 proteins in mouse lungs (Figure 6a, b).  193 
 194 
Because alveolar epithelial cells were a source of PAFR in the lung tissue of DSS 195 
animals and microbial ChoP is a ligand for PAFR,21 we examined whether ChoP was sufficient 196 
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to drive PAFR expression. Human alveolar epithelial cells (A549) were challenged by LPS 197 
isolated either from ChoP positive and ChoP negative bacteria, and PAFR proteins were 198 
measured in cell lysate by immunoblot. LPS stimulation from ChoP positive bacteria 199 
significantly increased PAFR proteins in epithelial cells, whereas PAFR protein levels did not 200 
change after LPS challenge from ChoP negative bacteria (Figure 6c). We next investigated 201 
whether PAFR interaction with ChoP directly regulated NLRP3 inflammasome activation in 202 
A549 cells.  Challenge with ChoP-positive LPS significantly increased NLRP3, pro-caspase 203 
and mature caspase protein expression, however treatment with CV6209 1 hour prior to ChoP 204 
challenge, significantly reduced ChoP-driven expression of all 3 proteins (Figure 6d, e). LPS 205 
from ChoP negative bacteria did not increase NLRP3 inflammasome protein levels. 206 
Antagonism of PAFR also significantly reduced secreted IL-1b proteins in cell supernatant 207 
after challenge with ChoP positive LPS (Figure 6f).  208 
 209 
Antibiotic treatment reduces ChoP positive bacteria in lungs and regulates NLRP3 210 
involved inflammasome in colitis-induced lung inflammation 211 
Given the evidence that ChoP-PAFR interactions activated the NLRP3-mediated 212 
inflammasome in the lungs of DSS-treated animals, we investigated whether reducing 213 
microbial load in the lungs through antibiotic treatment would affect inflammasome activation 214 
during colitis. To this end, we treated mice with amoxicillin, either intranasally or 215 
intragastrically, during DSS challenge. Intranasal amoxicillin treatment did not influence DSS 216 
disease course as measured by body weight, however DSS animals receiving intragastric 217 
delivery of amoxicillin had significantly higher weight loss compared to DSS animals receiving 218 
vehicle (Supplementary Figure S4a, b). Both intranasal and intragastric deliveries of 219 
amoxicillin led to significantly decreased total bacterial 16S expression in mouse lungs 220 
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following DSS challenge, and 16S expression for ChoP positive bacteria, such as Klebsillia. 221 
pneumoniae and Pseudomonas. aeruginosa was also reduced in mouse lungs (Figure 7a, b).   222 
 223 
To investigate whether this reduced bacterial load influenced PAFR expression in 224 
colitis-induced lung inflammation, we measured PAFR and NLRP3-involved inflammasome 225 
proteins in mouse lungs after DSS challenge with and without amoxicillin treatment. 226 
Interestingly, intranasal antibiotic treatment did not change DSS-induced PAFR proteins levels 227 
in mouse lungs (Figure 7c), however, NLRP3 and mature caspase-1 proteins were decreased 228 
in these animals when compared to DSS challenge with intranasal PBS treatment. Pro-caspase-229 
1 proteins were not altered after DSS challenge. Similarly, intragastric amoxicillin treatment 230 
had no effect on the levels of PAFR in mouse lungs (Figure 7d) but led to significantly 231 
decreased NLRP3 and mature caspase-1 proteins.  232 
Histological scoring of lung inflammation in DSS animals with and without amoxicillin 233 
treatment showed that antibiotics reduced inflammation and neutrophil recruitment in mouse 234 
lungs (Supplementary Figure S4c–d). Both intranasal and intragastric amoxicillin treatment 235 
decreased DSS-induced TNF, IL-1b and IL-6 protein in mouse lungs (Supplementary Figure 236 
S5). These data suggest that bacterial burden does not regulate PAFR expression in itself, but 237 
is required for downstream PAFR inflammasome activation. 238 
 239 
DISCUSSION 240 
Secondary organ pathologies are common in IBD and there is increasing interest in the mucosal 241 
cross-talk between the gut and lung in inflammatory diseases.7,9 Our previous work has 242 
demonstrated that systemic inflammation is a driving factor in lung inflammation common to 243 
animal models of colitis.22 In this study, we identify expression of PAFR and PAFR-mediated 244 
inflammasome activation as regulators of neutrophil recruitment to the lung when microbial-245 
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burden is increased. In two distinct models of colitis, increased lung PAFR expression was 246 
associated with increased airway inflammation, neutrophils in the BALF and increased 247 
bacterial burden in the lungs. PAFR expression was localized to epithelial cells and neutrophils 248 
and associated with NET-formation in the lung tissue of DSS colitis animals. Immunoblot 249 
analysis identified increased NLRP3 inflammasome activation in DSS animals leading to IL-250 
1β secretion in lung tissues and these responses were inhibited by antagonism of PAFR. 251 
Mechanistic studies indicated that PAFR mediates NLRP3 activation and caspase-1 cleavage 252 
in response to interactions between microbial ChoP and PAFR21, and that reduction of 253 
microbial load with antibiotics is sufficient to reduced inflammasome activation in the lungs 254 
of DSS animals, but not PAFR expression. These data suggest that PAFR acts as a pattern 255 
recognition receptor (PRR) for ChoP and is a mucosal mediator of the NLRP3 inflammasome. 256 
 257 
PAFR is a hypoxia-responsive G protein coupled receptor18 on multiple cell types in 258 
lungs, and the increased expression of PAFR has been observed in many inflammatory-driven 259 
airway diseases, particularly those with an infectious component.29 PAFR protein is increased 260 
in both large and small airway epithelium and alveolar epithelial cells in COPD patients30 and 261 
PAFR mRNA levels are increased in asthmatics compared to controls.19 The ChoP moiety of 262 
bacterial lipoteichoic acid has a strong binding affinity to PAFR and this finding, coupled with 263 
observed co-localization of PAFR with Gram-positive bacteria such as Streptococcus 264 
pneumonia in pulmonary disease,31 has led to the suggestion that microbes may exploit PAFR 265 
through molecular mimicry15, 16 to gain access to the serosa during mucosal inflammation.18 266 
However, ChoP expression is regulated by phase variation in both Gram-negative and Gram-267 
positive bacteria and that upregulation of ChoP confers survival advantages during 268 
colonization.22 Thus ChoP may instead be a pathogen-associated molecular pattern recognized 269 
by PAFR at the onset of ischemic inflammation to prevent or limit bacterial colonization. 270 
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Supporting this, ChoP is also recognized by circulating C-reactive protein which leads to 271 
activation of the compliment response.32 Here, our data show that NLRP3-mediated 272 
inflammasome activation is prevented both in vivo and in vitro by PAFR antagonism. Fillon et 273 
al have previously proposed PAFR as a PRR that recognises intravascular ChoP-containing 274 
cell wall components33. This suggests that PAFR induced inflammasome responses may occur 275 
during colitis-associated bacteraemia and that colonization of the lung is not critical to the 276 
response. This may explain why antibiotic treatment prevented lung NLRP3 inflammasome 277 
activation but did not reduce PAFR expression, as cell wall components may be sufficient to 278 
increase PAFR, but live-bacteria are required to induce an inflammasome response. 279 
Additionally, toll-like receptors (TLR), particularly TLR2 and TLR4, may be important in 280 
mediating the PAFR inflammasome response. Studies by Knapp et al. have shown the relative 281 
importance of TLR2 over TLR4 and PAFR in in regulating inflammatory responses to 282 
lipoteichoic acid (LTA) during pulmonary infection.34  In contrast to TLR2, deletion of TLR4 283 
and PAFR only partially protected mice for LTA-induced lung injury. However, TLR2 and 284 
TLR4 are basolaterally expressed proteins, while PAFR is apically expressed18. Therefore, 285 
PAFR may act as an apical PRR, or alternatively shuttle ChoP-containing bacterial proteins to 286 
TLR2 and TLR4 on the basolateral membrane of the epithelium.  287 
 288 
It is unclear how the lung is exposed to ChoP positive bacteria during colitis. One 289 
possibility is that the loss of intestinal barrier integrity allows bacteria to translocate to other 290 
organs, such as lung via blood vessels. Attempts by these bacteria to colonize the lung may 291 
utilise ChoP 22and ChoP-positive opportunistic pathogens such as P. aeruginosa are abundant 292 
in the GI tract35. However, because ChoP may be transiently expressed by bacteria22, it is 293 
difficult to demonstrate this in vivo. Alternatively, the local lung microbiota may sense and 294 
respond to the altered epithelial cell metabolism due to inflammation. Some microbial species 295 
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sense inflammatory hypoxia through increases in adenosine signalling, upregulating virulence 296 
factors to facilitate cell adhesion36. As epithelial PAFR is also hypoxia-regulated18, PAFR-297 
mediated inflammasome activation may represent an important innate response to counteract 298 
opportunistic colonisation.  In support of this hypothesis, we found alveolar epithelial cells to 299 
be a major source of PAFR in mouse lungs after DSS challenge and PAFR+ epithelial cells had 300 
increased NLRP3 and IL-1b protein levels.  301 
 302 
In our previous studies we have shown that neutrophil-driven lung inflammation is a 303 
feature of experimental models of colitis in mice.7 It reflects the findings that neutrophil-304 
mediated lung diseases are the most common type of pulmonary manifestation of IBD.10  305 
Studies in PAFR–/– mice suggest that PAFR is important for the recruitment of neutrophils to 306 
the lung in models of infection and experimental asthma.37 In agreement with these findings, 307 
we found that antagonism of PAFR significantly reduced pulmonary neutrophils and NETosis 308 
in the lung during colitis. Recent studies show that PAF-signalling activates human neutrophils 309 
and induces NETs38. Release of NETs by neutrophils prevents bacterial dissemination, 310 
however some studies suggest that rather than killing bacteria, NET-induced tissue damage 311 
may actually facilitate bacterial replication.39 This may explain why in pulmonary disease, 312 
recognition of ChoP by PAFR is not sufficient to clear the infection, and in the context of IBD, 313 
this may explain why these patients have a higher risk of developing pneumonia. This risk is 314 
further increased with use of corticosteroids, and in this respect, it is interesting to note that 315 
glucocorticoid use increases PAFR expression in the lungs of patients with COPD.40    316 
 317 
The activation and release of IL-1b plays a major role in acute inflammatory responses 318 
to respiratory infection and promotes clearance of pathogens. However, excessive 319 
inflammasome activation and production of IL-1b result in development of several chronic 320 
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respiratory diseases, including asthma and COPD.41 The exact mechanism of NLRP3 321 
inflammasome activation in lung inflammation has remained poorly understood, our finding 322 
of a signalling axis between PAFR-NLRP3 and IL-1b mediated neutrophil recruitment is 323 
consistent with observations in pulmonary infection models (Supplementary Figure S6). For 324 
instance, IL-1b–/– mice fail to recruit neutrophils from bone marrow to lungs in a model of 325 
bacteria induced lung infection.42, 43 Our histological analysis in mouse lungs demonstrates that 326 
neutrophils are predominantly localize around blood vessel after DSS challenge and that PAFR 327 
expression is also localized to lung neutrophils. L-selectin is an important mediator on 328 
leukocyte surfaces and is constitutively expressed on the endothelium.44 L-selectin plays a role 329 
in neutrophil rolling, however neutrophil migration into inflamed tissue is impaired in L-330 
selectin–/– mice.45 Because increased PAFR levels are associated with decreased L-selectin 331 
expression on neutrophil surfaces PAFR may also trap neutrophils within the lung, further 332 
exacerbating inflammation.46 333 
 334 
Taken together, our data show that PAFR plays critical roles in colitis-induced lung 335 
inflammation. Our data is the first to demonstrate that PAFR regulates IL-1b protein activation 336 
via the NLRP3 inflammasome signaling pathway. PAFR may act as an inflammasome-337 
activating PRR during colonization of the lung following colitis-induced bacteraemia. 338 
Inhibition of PAFR reduced inflammation in mouse lungs after DSS challenge and PAFR may 339 
represent a previously unappreciated mediator of secondary lung inflammation in conditions 340 
such as IBD and acute lung inflammation.  341 
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METHODS 342 
Experimental colitis-induced lung inflammation  343 
For the DSS colitis model, WT female C57BL/6 mice (6–8 weeks old) received 4% 344 
weight/volume dextran sulfate sodium (DSS; M.Wt. 36,000 – 50,000; MP Biomedicals, Santa 345 
Ana, USA) in drinking water ad libitum for 7 days as previously described.7, 47 Age matched 346 
controls received normal drinking water. For PAFR antagonism, mice were administered with 347 
2.5 mg/kg CV6209 (a PAFR antagonist, Cayman Chemical, Michigan, USA) in sterile PBS 348 
either intranasally48 or intravenously from day 4 to 6 during DSS challenge, while control mice 349 
received equal volume of sterile PBS. For antibiotic treatment, mice received 350 
amoxicillin/clavulanate potassium (5 mg/kg, Sigma-Aldrich, St. Louis, USA) either 351 
intranasally or intragastically from day 0 to day 4 of 7 days DSS challenge, and control mice 352 
received equal volume of sterile PBS.  353 
 354 
For the anti-CD40 model of colitis, RAG1–/– female mice on C57BL/6 background (6–355 
8 weeks old) were intraperitoneally injected with monoclonal anti-CD40 antibody (200 356 
µg/mouse, FGK45, Bxcell, West Lebanon, USA) for 9 days as previously described.49 Controls 357 
received equal amount of IgG antibody (Bxcell, West Lebanon, USA). All mouse experiments 358 
were approved by the Animal Ethics Committee of the University of Newcastle. 359 
 360 
Murine endoscopy  361 
Mucosal inflammation was assessed by colonoscopy on day 3, 5 and 7 of DSS challenge and 362 
on day 2, 4, 6 and 8 of anti-CD40 challenge using the Coloview® small animal gastrointestinal 363 
endoscope (Karl Storz Endoscopy, Tuttlingen, Germany).50 Representative images were 364 
captured from HD videos. 365 
 366 
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Bronchoalveolar lavage fluid (BALF) 367 
BALF were collected by washing mouse airways twice with 500 µL PBS, and then incubated 368 
with red blood cell lysis buffer (150 mM NH4Cl, 10 mM NaHCO3 and 1.26 mM EDTA) at 369 
4 °C for 5 minutes. Total cells in airways were counted after centrifugation (187 g, 4 °C, 10 370 
minutes), and remaining cells were than cyto-centrifugated (300 g, 5 minutes) on microscope 371 
slides. The cells were stained with May-Gruwald-Giemsa and identified according to 372 
morphological criteria using a light microscope as previously described.48 373 
 374 
Lung histological scoring  375 
Mouse tissues were fixed, paraffin-embedded, sectioned (4-6 µm) and stained with 376 
hematoxylin and eosin (H&E). Histopathology sections were scored blinded, according to a set 377 
of custom-designed criteria as described previously.7 378 
 379 
mRNA expression  380 
Mouse lungs were collected, and total RNA were extracted by TRIzol (Invitrogen, Carlsbad, 381 
USA) reagent method. RNA (1,000 ng) was treated with DNase (Sigma-Aldrich, St. Louis, 382 
USA) and reverse-transcribed using iScript according to manufactory’s instrument (Biorad, 383 
Hercules, USA). Total bacterial 16S (F:CGTCAGCTCGTGTTGTGAAA; 384 
R:GGCAGTCTCCTTGAGTTCC), Klebsillia. pneumoniae 385 
(F:CATCTCGATCTGCTGGCCAA; R:GCGCGGATCCAGCGATTGGA), Pseudomonas 386 
aeruginosa (F:AGTTGTCGCGGCGCTACTAC; R:GCTCACCTGGATCTGGTCC) and 387 
mouse b-actin (F:GGAGAAAATCTGGCACCACA; R:AGAGGCGTACAGGGATAGCA) 388 
mRNA expressions were determined using real-time qPCR by a CFX touch real-time PCR 389 
detection system (Biorad, Hercules, USA). Relative expressions of target mRNA expressions 390 
were determined to the reference b-actin gene.  391 
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 392 
Protein extraction  393 
Proteins were extracted from mouse tissue homogenates and cell culture lysates using radio 394 
immunoprecipitation assay buffer (RIPA; Sigma-Aldrich, St. Louis, USA), supplemented with 395 
protease and phosphatase inhibitors (Thermo Fisher Scientific, Waltham, USA). 396 
Homogenization was performed using a TissueLyser LT (Qiagen, Hiden, Germany) as 397 
previously described.51 Lysed samples were centrifuged (8,000 g, 10 minutes, 4 °C) and 398 
supernatants were collected from centrifuged for assessment by enzyme linked immunoblot 399 
and immunosorbent assay (ELISA). Total protein concentrations were measured using Pierce 400 
BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, USA) according to 401 
manufacturer’s instructions. 402 
 403 
Immunoblot 404 
Total proteins were separated by electrophoresis using Mini-Protean TGX stain free 405 
polyacrylamide gels (Bio-Rad, Hercules, USA) and transferred onto polyvinylidene difluoride 406 
(PVDF) membranes. The membranes were blocked with 5% BSA (Sigma-Aldrich, St. Louis, 407 
USA) for 2 hours at room temperature (RT), and then incubated with anti-PAFR (1:1,000, sc-408 
8744, Santa Cruz Biotechnology, Santa Cruz, USA), anti-NLRP3 (1:1,000, ab4207, Abcam, 409 
Cambridge, UK), anti-caspase-1 (1:1,000, NBP1-45433, Novus biologicals, Littleton, USA), 410 
anti-b-actin (1:10,000, ab8227, Abcam, Cambridge, UK) and anti-vinculin (1:5,000, 411 
MAB6896, R&D System) at 4 °C overnight. Blots were incubated with anti-goat or anti-rabbit 412 
IgG HPR conjugated antibodies (R&D System, Minneapolis, USA). Images of immunoblots 413 
were captured with a ChemiDoc MP System (Bio-Rad, Hercules, USA). Densitometry analysis 414 
was performed relative to houskeeping proteins b-actin or vinculin, using ImageJ (NIH, 415 




Longitudinal mouse lung sections were deparaffinized and incubated with citrate buffer (10 419 
mM citrate acid, 0.05% tween 20, pH 6) at 100 °C for antigen retrieval (35 minutes). The slides 420 
were then blocked with casein (Thermo Fisher, Waltham, USA) at RT for 1 hour, and incubated 421 
with anti-PAFR (1:50, Santa Cruz Biotechnology, Santa Cruz, USA) at 4 °C overnight and 422 
followed by anti-goat Cy3 conjugated secondary antibody (R&D System, Minneapolis, USA) 423 
at RT for 1 hour. The slides were then incubated with F4/80 (1:100, FITC conjugated) and 424 
Ly6G (1:100, BV421 conjugated, BD Biosciences, Franklin Lakes, USA) at RT for 1 hour. 425 
Some slides were stained with myeloperoxidase (MPO, 1:100, PA5-16672, Thermo Fisher, 426 
Waltham, USA) and histone H1 (1:200, Mab3864, Merck, Kenilworth, USA) antibodies and 427 
followed by anti-rabbit Cy3 and anti-mouse FITC secondary antibodies from Abcam, 428 
Cambridge, UK. Nuclei were stained with DAPI (Thermo Fisher, Waltham, USA). Random 429 
pictures (20 images under 40x magnification) were taken from mouse lung sections, and MPO+ 430 
and histone H1+ cells were enumerated using ImageJ (NIH, Bethesda, USA).  All fluorescent 431 
signals were quantified using an Axio Imager M2 microscope (Zeiss, Oberkochen, German) as 432 
previously described.48 433 
 434 
ELISA 435 
The concentrations of TNF and IL-1b in mouse lung and colon homogenates and human cell 436 
lysates were determined using DuoSet ELISA kits (R&D systems, Minneapolis, USA) 437 
according to manufacturer’s instructions.  438 
 439 
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Flow cytometry 440 
Single cell suspensions were obtained from mouse lungs using gentleMACSTM Dissociators 441 
(Mitenyi Biotec, Australia). Cells were incubated with Fc blocker (BD Pharmingen, Franklin 442 
Lakes, USA) and stained with CD45 (conjugated with PE-Cy7, BD Biosciences, Franklin 443 
Lakes, USA), F4/80 (Conjugated with FITC, BD Pharmingen, Franklin Lakes, USA), CD11b 444 
(conjugated with Alexa Fluor 700, BD pharmingen, Franklin Lakes, USA) and Ly6G 445 
(conjugated with BV510) antibodies at 4 °C for 30 minutes. For some experiments, cells were 446 
separated by MojoSortTM Mouse CD45 Nanobeads (BioLegend, San Diego, USA) according 447 
to manufacturer’s instrument. All CD45 negative cells were stained with Epcam (conjugated 448 
with BV421, BioLegend, San Diego, USA) and PAFR (ab104162, Abcam, Cambridge, UK) 449 
at 4 °C for 30 minutes, and then followed by anti-rabbit FITC conjugated secondary antibody 450 
at 4 °C for 30 minutes. CD45 positive cells were stained with F4/80 (BUV395, BD pharmingen, 451 
Franklin Lakes, USA), Ly6G (PE-CF594, BioLegend, San Diego, USA), CD11b (BV480, 452 
BioLegend, San Diego, USA), CD11c (PE, BioLegend, San Diego, USA), SigF (BV421, 453 
BioLegend, San Diego, USA), CD45 (PE-Cy7, BD Biosciences, Franklin Lakes, USA) and 454 
PAFR (Abcam, Cambridge, UK) at 4 °C for 30 minutes, and then followed by anti-rabbit FITC 455 
conjugated secondary antibody at 4 °C for 30 minutes. Flow cytometric analysis was performed 456 
using a BD LSRFortessaTM flow cytometer with FACSDiva software (BD Biosciences, 457 
Franklin Lakes, USA). Data was analysed using FlowJo software (Tree Star Inc., Ashland, 458 
Oregon, USA) as previously described.50CD45–Epcam+PAFR+ cells were sorted by a BD 459 
FACSAria III cytometer and collected into DMEM medium. Cell lysates were collected, and 460 
total proteins were extracted for immunoblot. For cell sorting assays, all samples were stained 461 
and analysed by flow cytometry within 3 hours without fixation and live/dead cell stain. 462 
 463 
Cell culture 464 
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Human alveolar basal epithelial cell line (A549, ATCC, USA) were cultured in DMEM 465 
medium contained 10% fetal bovine serum, 1% non-essential amino acids, 100 units/ml 466 
penicillin and 100 mg/ml streptomycin at 37 °C with 5% CO2. Cells were treated with 100 µM 467 
CV6209 (Cayman Chemical, Ann Arbor, USA) 1 hour before a 4-hours LPS challenge. LPS 468 
was sourced from P. aeruginosa (ChoP positive, 1µg/ml, Sigma-Aldrich, St. Louis, USA) or 469 
from E. coli (ChoP negative, 1µg/ml, Sigma-Aldrich, St. Louis, USA). Control groups received 470 
equal volume of media.  471 
 472 
Statistical analysis 473 
Results are presented as standard error of the mean (SEM). For mouse studies, 6–8 mice were 474 
used per group, sourced from duplicate experiments. Cell culture experiments were repeated 475 
at least three times for each time point. Comparisons between two groups were made using 476 
unpaired t-Tests. Comparisons between multiple groups were made using a one-way analysis 477 
of variance (ANOVA) with Bonferroni comparisons. For analysis of data with two independent 478 
variables such as weight loss data, a two-way ANOVA was utilized. Analyses were performed 479 
using the GraphPad Prism Software (San Diego, USA). 480 
 481 
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Figure legends 693 
Fig. 1 Experimental models of colitis induces lung inflammation in mice. Mice received 694 
DSS in drinking water over 7 days. Control mice received plain water. Mouse body weight (a) 695 
and colonic endoscopy (b, arrows indicate lesions) were assessed during time-course of DSS 696 
challenge. (c) Total leukocytes and cell differential counts, including macrophages and 697 
neutrophils were enumerated in bronchoalveolar fluid (BALF). (d) Mouse lungs were 698 
collected, and lung sections were stained with H&E, arrows indicate inflammation. (e) Mouse 699 
lung inflammation scores were assessed after 7 days DSS challenge. Mice were injected with 700 
monoclonal anti-CD40 antibody for 9 days. Control mice received IgG antibody. Mouse body 701 
weight (f) and colonic endoscopy (g, arrows indicate lesions) were assessed during time-course 702 
of anti-CD40 antibody challenge. (h) Total leukocytes and cell differential counts, including 703 
macrophages and neutrophils were enumerated in BALF. (i) Mouse sections were stained with 704 
H&E, arrows indicate inflammation. (j) Mouse lung inflammation scores were assessed after 705 
9 days anti-CD40 antibody challenge. n=6–8, mean ± SEM. Statistical analysis was assessed 706 
by two-way ANOVA (a and f) and Student’s t-test (c, e, h and j), *P<0.05, **P<0.01, 707 
***P<0.001, ****P<0.0001 compared to control mice.  708 
 709 
Fig. 2 PAFR expression and cellular sources of PAFR in mouse lungs. (a) Bacterial 16S 710 
expression was measured in mouse lungs by qPCR after 7 days DSS challenge. (b) PAFR 711 
protein in mouse lungs was measured after 7 days DSS challenge by immunoblot (left), and 712 
fold change of densitometry of PAFR normalized to vinculin (right). (c) Bacterial 16S 713 
expression was measured in mouse lungs by qPCR after 9 days anti-CD40 antibody challenge. 714 
PAFR protein in mouse colons was measured after 9 days anti-CD40 antibody challenge by 715 
immunoblot (left), and fold change of densitometry of PAFR normalized to vinculin (right). 716 
(e) Lung sections from DSS or control animals were stained with PAFR (red) and ly6G (blue) 717 
 29 
by immunofluorescence. Auto-fluorescence in FITC shows cell morphology; scale bar: 200 718 
µm. Single cells were obtained from mouse lungs, and CD45–Epcam+PAFR+ (epithelial cells, 719 
f), CD45+F4/80+PAFR+ (macrophages, g) and CD45+CD11b+Ly6G+PAFR+ cells (neutrophils, 720 
h) were enumerated by flow cytometry. n=6–8, mean ± SEM. Statistical analysis was assessed 721 
by Student’s t-test. *P<0.05, **P<0.01 compared to control mice. 722 
 723 
Fig. 3 DSS-induced inflammation and activated inflammasomes in alveolar epithelial cells 724 
and mouse whole lungs. Protein levels of TNF (a) and IL-1b (b) proteins in mouse lungs were 725 
measured by ELISA. (c) NLRP3, pro-caspase-1, mature caspase-1 and b–actin proteins were 726 
measured in mouse colon after DSS challenge by immunoblot. (d) Fold change of the proteins 727 
normalized to b–actin. CD45–Epcam+PAFR+ were isolated from the lungs of DSS and control 728 
animals and sorted by flow cytometry. (e) NLRP3, pro-caspase-1, mature caspase-1 and b–729 
actin proteins were measured in cell lysates by immunoblot. (f) Fold change of the proteins 730 
normalized to b–actin. (g) IL-1b protein in mouse epithelial cells was measured by ELISA. 731 
n=6–8, mean ± SEM. Statistical analysis was assessed by Student’s t-test. *P<0.05, **P<0.01, 732 
***P<0.001 compared to control mice. 733 
 734 
Fig. 4 Influence of PAFR antagonism on colitis-induced lung inflammation in mice. Mice 735 
were treated with CV6209 intranasally (i.n) or intravenously (i.v) on day 4, 5, and 6 of DSS 736 
model and control mice received i.n. or i.v. PBS. Bronchoalveolar lavage fluid (BALF) was 737 
collected, and total leukocytes (a), macrophages (b) and neutrophils (c) were enumerated after 738 
cytospin. (d) Mouse lungs were collected, and lung sections were stained with H&E. Scale bar: 739 
200 µm. Arrows indicate inflammation. (e) Lung inflammatory scores were assessed after 7 740 
days DSS challenge with CV6209 treatments. The levels of TNF (f), IL-1b (g) and IL-6 (h) 741 
proteins in mouse lungs were measured by ELISA. n=6, mean ± SEM. Statistical analysis was 742 
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assessed by one-way ANOVA *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared to 743 
control mice. #P<0.05, ##P<0.01, ####P<0.0001 compared to mice receiving DSS and treated 744 
with PBS (i.n). $P<0.05, $$$P<0.001, $$$$P<0.0001 compared to mice receiving DSS and 745 
treated with PBS (i.v).  746 
 747 
Fig. 5 Influence of PAFR antagonism on neutrophil responses in mouse lungs after DSS 748 
challenge. Mice were treated with CV6209 intranasally (i.n) or intravenously (i.v) on day 4, 5, 749 
and 6 of DSS model and control mice received i.n. or i.v. PBS. Single cell suspensions were 750 
obtained from mouse lungs, and stained with CD45, CD11b, F4/80 and Ly6G (a), and 751 
CD45+CD11b+Ly6G+F4/80– cells (b) and CD45+F4/80+ cells (c) were enumerated by flow 752 
cytometry. (d) Mouse lung sections were stained with myeloperoxidase (MPO, red), histone 753 
H1 (green) and DAPI (blue) by immunofluorescence. Scale bar: 200 µm. The indicated regions 754 
are shown the expanded at bottom line. Arrows indicate NETs. Scale bar: 20 µm. (e) MPO+ 755 
and histone H1+ cells were enumerated on mouse lung sections. n=6, Results are mean ± SEM. 756 
Statistical analysis was assessed by one-way ANOVA *P<0.05, **P<0.01, ***P<0.001, 757 
****P<0.0001 compared to control mice. #P<0.05, ##P<0.01 compared to mice receiving DSS 758 
and treated with PBS (i.n). $P<0.05 compared to mice receiving DSS and treated with PBS 759 
(i.v). 760 
 761 
Fig. 6 Activation of NLRP3 inflammasome signalling though PAFR. Mice were treated 762 
with CV6209 intranasally (i.n) on day 4, 5, and 6 of DSS model and control mice received i.n. 763 
or i.v. PBS. (a) NLRP3, caspase-1 and b–actin proteins in whole lungs were assessed by 764 
immunoblot, and (b) fold change of these proteins were determined by densitometry 765 
normalized to b–actin. For in vitro analyses, human alveolar epithelial cells were treated with 766 
CV6209 or vehicle and stimulated with phosphorylcholine (ChoP) positive or negative LPS 767 
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for 4 hours. (c) PAFR proteins in the cell lysates were assessed by immunoblot, and 768 
densitometry was normalized to b–actin. (d) NLRP3, caspase-1 and b–actin proteins in the cell 769 
lysates were assessed by immunoblot, and (e) fold change of these proteins was determined by 770 
densitometry normalized to b–actin. (f) IL-1b proteins were assessed in cell supernatant by 771 
ELISA. n=5-6. Results are mean ± SEM. Statistical analysis was assessed by one-way ANOVA 772 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 as compared to control mice or cell treated 773 
with media. #P<0.05, #P<0.01 compared to mice received DSS and treated with PBS (i.n). 774 
$P<0.05 compared to cells received LPS from ChoP positive bacteria. 775 
 776 
Fig. 7 Influence of antibiotics on bacteria load and the PAFR-NLRP3 inflammasome axis 777 
in the lungs of DSS mice. Mice received amoxicillin/clavulanic acid (5mg/kg) either 778 
intranasally (i.n) or intragastrically (i.g) over the course of DSS challenge. (a) Total bacteria 779 
16S, K. pneumoniae and P. aeruginosa expression in mouse lungs after i.n antibiotics. (b) Total 780 
bacteria 16S, K. pneumoniae and P. aeruginosa expression in mouse lungs after i.g antibiotics. 781 
(c) PAFR, NLRP3, caspase-1 and b–actin proteins in mouse lungs after i.n. antibiotics 782 
treatment were assessed by immunoblot (top), and fold change of these proteins were 783 
determined by densitometry normalized to b–actin (bottom). (d) PAFR, NLRP3, caspase-1 and 784 
b–actin proteins in mouse lungs after i.g. antibiotics treatment were assessed by immunoblot 785 
(top), and fold change of these proteins were determined by densitometry normalized to b–786 
actin (bottom).  n=6, mean ± SEM. Statistical analysis was assessed by one-way ANOVA. 787 
*P<0.05, **P<0.01, ****P<0.0001 compared to control mice. #P<0.05, 788 
####P<0.0001compared to mice received DSS and treated with antibiotics (i.g). $P<0.05, 789 
$$$P<0.001 compared to mice received DSS and treated with antibiotics (i.n). 790 
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